hu3CAB43 Frozen Validation Report
342 PRS models · 1,636 protein predictions · 138 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Blood sugar and body-composition divergence
near-term focus
Sugar-handling signals are elevated, but body-size, waist, triglyceride, and some glucose-tolerance signals lean protective. This is a lean-metabolic divergence rather than a simple weight-risk pattern.
Full explanation
Your genetic evidence points in two directions. Several signals lean toward higher blood-sugar strain, while body size, waist size, triglycerides, and some glucose-tolerance context lean lower than average.
That means a naturally leaner body profile would not necessarily cancel the sugar-handling signal. The practical takeaway is to prioritize steady energy, muscle maintenance, and meals that avoid sharp glucose swings, even if weight loss is not the goal.
This becomes worth discussing or reviewing if blood-sugar labs, eye findings, unusual thirst or urination, energy crashes after meals, or a family history of diabetes make sugar handling relevant. In everyday life, training and meal structure are the most useful levers.
What to watch forPrioritize protein-and-fiber anchored meals, regular resistance training, and steady aerobic work; review this theme if blood-sugar labs, eye findings, or family history make it relevant.
Show technical evidence
Risk-score evidence
- diabetes: risk percentile 99.1%, coverage 90%, PGS001327.
- glucose: risk percentile 97.6%, coverage 100%, PGS001952.
- non insulin dependent diabetes: risk percentile 92.1%, coverage 90%, PGS001294.
- incident type 2 diabetes: risk percentile 1.2%, coverage 99%, PGS002779.
- triglyceride levels: risk percentile 7.2%, coverage 97%, PGS003401.
- two hour glucose during ogtt: risk percentile 11.2%, coverage 95%, PGS000839.
Protein pathway context
- ACP6: predicted level percentile 96%, R2 0.6207; pathway context only.
- CGA: predicted level percentile 4.2%, R2 0.5201; pathway context only.
- TREH: predicted level percentile 87.9%, R2 0.5404; pathway context only.
- APOBR: predicted level percentile 18.7%, R2 0.67; pathway context only.
Candidate variants
- Variant rs10105606 CC: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- LOC107984063 rs10211524 GG: snpedia_context.
- PCSK5 rs11144688 GG: snpedia_context.
Clotting, rhythm, and blood-pressure background
near-term focus
Vein-clotting, vein-inflammation, rhythm, blood-pressure, and coronary signals are elevated, with some protective stroke and electrical-timing context.
Full explanation
The cardiovascular pattern leans toward vascular awareness. The strongest signals involve clotting or vein inflammation, rhythm background, blood-pressure tendency, and coronary artery context.
This does not mean a clot, rhythm problem, or heart disease is present. It means that if real-world signs ever point in that direction, the genetics gives those signs more context than a random one-off result would.
There is also nuance: some stroke and electrical-timing evidence leans protective. This becomes worth discussing if there are palpitations, chest discomfort, unexplained shortness of breath, one-sided leg swelling, a personal or family history of clots, or if an antiplatelet medicine is ever being considered.
What to watch forTreat clotting symptoms, new palpitations, exertional chest symptoms, or a family clotting history as reasons to review this profile with a clinician.
Show technical evidence
Risk-score evidence
- blood clot or deep vein thrombosis: risk percentile 98.9%, coverage 85%, PGS000931.
- phlebitis and thrombophlebitis: risk percentile 97.3%, coverage 86%, PGS000961.
- deep vein thrombosis: risk percentile 89.6%, coverage 89%, PGS001266.
- incident atrial fibrillation: risk percentile 96.6%, coverage 100%, PGS002773.
- high blood pressure age at diagnosis: risk percentile 95.6%, coverage 88%, PGS000935.
- coronary atherosclerosis: risk percentile 94.5%, coverage 100%, PGS001839.
Protein pathway context
- MMP3: predicted level percentile 96.2%, R2 0.5052; pathway context only.
- CFHR2: predicted level percentile 8.7%, R2 0.7304; pathway context only.
- IL1RL1: predicted level percentile 18.1%, R2 0.5009; pathway context only.
Candidate variants
- LOC105377979 rs1015451 TT: snpedia_context.
- SLC9A4 rs1014286 AA: snpedia_context.
Medication-response context
- CYP2C19: Rapid Metabolizer, *1/*17; affected medicines include Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole.
Blood-cell pattern and clotting nuance
useful to review
Blood-cell size, distribution, neutrophil, platelet-size, and platelet-count signals are mixed but meaningful. Routine blood-count context may be unusually informative.
Full explanation
Several signals point toward blood-cell traits: red-cell size, red-cell distribution, neutrophil percentage, platelet size, and broader hematology context. The directions are not all the same, which is why this is a pattern rather than a single conclusion.
This is not evidence of a blood disorder. It is better read as a reason that ordinary blood-count information, if available, could explain more than usual about energy, inflammation, clotting context, or recovery from illness.
This becomes worth discussing if a blood count is repeatedly abnormal, if there is unexplained fatigue, easy bruising, unusual bleeding, recurrent clots, or a family history of blood-cell disorders. Without those triggers, it is background context rather than a standalone concern.
What to watch forKeep this as context for future blood-count results, especially if fatigue, bruising, bleeding, clotting history, or repeated abnormal results appear.
Show technical evidence
Risk-score evidence
- mean corpuscular hemoglobin: risk percentile 96.8%, coverage 100%, PGS001989.
- mean corpuscular volume: risk percentile 93.8%, coverage 100%, PGS001990.
- neutrophil percentage: risk percentile 97.5%, coverage 96%, PGS003943.
- mean plateletvolume: risk percentile 87.6%, coverage 96%, PGS003934.
- red blood celldistribution width: risk percentile 86.4%, coverage 100%, PGS001908.
- platelet count: risk percentile 5%, coverage 96%, PGS003932.
Protein pathway context
- HBZ: predicted level percentile 9.1%, R2 0.5431; pathway context only.
- MBL2: predicted level percentile 81.7%, R2 0.6024; pathway context only.
- FOLR3: predicted level percentile 81.8%, R2 0.9226; pathway context only.
Candidate variants
- Variant rs11104870 TT: snpedia_context.
- RCL1 rs10758658 GG: snpedia_context.
- ATP2B4 rs10900585 TT: snpedia_context.
- APOA1-AS,SIK3 rs10047462 TT: snpedia_context.
Eye and retina background
useful to review
Retinal and diabetes-related eye signals are elevated, while cataract, pressure, corneal, and detachment signals lean more protective.
Full explanation
Eye-related evidence is mixed but important. The clearest elevated signals involve diabetic eye disease and retinal disorders, which fit with the broader sugar-handling theme.
At the same time, several eye-structure signals lean protective, including cataract, eye pressure, corneal properties, and retinal detachment context. A complement-pathway signal adds retina-relevant background rather than proving any current eye disease.
This becomes worth discussing if vision changes, new floaters, retinal findings, elevated blood sugar, or a family history of retinal or macular disease becomes relevant. The most practical step is to connect eye context with metabolic context rather than treating them as separate stories.
What to watch forUse this as context for routine eye care, especially if blood-sugar results, vision changes, or family retinal history become relevant.
Show technical evidence
Risk-score evidence
- diabetic eye disease: risk percentile 98.7%, coverage 80%, PGS001028.
- retinal disorders in diseases classified elsewhere: risk percentile 96.7%, coverage 80%, PGS001276.
- cataract: risk percentile 0.4%, coverage 100%, PGS001837.
- intra ocular pressure goldmann correlated: risk percentile 12%, coverage 90%, PGS001411.
- retinal detachments and breaks: risk percentile 17.9%, coverage 85%, PGS000990.
- corneal hysteresis: risk percentile 13.8%, coverage 91%, PGS001381.
Protein pathway context
- CFHR2: predicted level percentile 8.7%, R2 0.7304; pathway context only.
- C1QTNF9: predicted level percentile 91.8%, R2 0.5406; pathway context only.
Candidate variants
- CFH rs1061170 TT: uncertain_or_conflicting; Factor H deficiency · Age related macular degeneration 4 · CFH-Related Dense Deposit Disease / Membranoproliferative Glomerulonephritis Type II · Hemolytic uremic syndrome, atyp....
Immune and gut-inflammation background
useful to review
Immune evidence is broad and mixed, with inflammatory and gut-related signals alongside protective allergy, eczema, psoriasis, and lupus context.
Full explanation
Your immune evidence is active rather than quiet. It includes inflammatory, gut-related, viral-response, and connective-tissue immune signals, supported by several immune-pathway protein signals.
The pattern is not one-directional. Some allergy, eczema, psoriasis, and lupus-related evidence leans protective, so this should not be read as a general autoimmune-risk label.
This becomes worth discussing if persistent gut changes, inflammatory joint symptoms, unusual skin or eye inflammation, recurrent unusual infections, or family autoimmune history enters the picture. In the absence of those triggers, the best use is awareness and lifestyle support for gut and immune resilience.
What to watch forKeep this as immune-gut context; review it if persistent bowel changes, inflammatory symptoms, unusual infections, or family autoimmune history becomes relevant.
Show technical evidence
Risk-score evidence
- crohn s disease: risk percentile 83.8%, coverage 83%, PGS001331.
- polymyalgia rheumatica: risk percentile 93.8%, coverage 100%, PGS001878.
- sarcoidosis: risk percentile 87%, coverage 100%, PGS001872.
- other systemic involvement of connective tissue: risk percentile 86.6%, coverage 86%, PGS000960.
- zoster herpes zoster: risk percentile 92.8%, coverage 84%, PGS001131.
- eczema dermatitis: risk percentile 0.7%, coverage 87%, PGS000944.
Protein pathway context
- TLR3: predicted level percentile 96.7%, R2 0.8019; pathway context only.
- CD200R1: predicted level percentile 1.6%, R2 0.5497; pathway context only.
- SIRPA: predicted level percentile 6.8%, R2 0.8273; pathway context only.
- LILRB5: predicted level percentile 92.5%, R2 0.7926; pathway context only.
- IL17RA: predicted level percentile 9%, R2 0.5078; pathway context only.
- FCGR2A: predicted level percentile 91.9%, R2 0.5811; pathway context only.
Candidate variants
- Variant rs11010067 GG: snpedia_context.
- Variant rs10892279 GG: snpedia_context.
- Variant rs10484561 TT: snpedia_context.
Digestive, gallbladder, and colorectal background
useful to review
Colorectal, diverticular, gallbladder, pancreatic, and inflammatory-bowel signals appear together, softened by protective liver and benign-colon context.
Full explanation
The digestive cluster is broader than one condition. It includes colorectal background, diverticular tendency, gallbladder inflammation, pancreatic internal-signaling context, and inflammatory-bowel evidence.
There is protective nuance too: benign-colon, chronic nonalcoholic liver, and gallstone-related evidence do not all point in the same direction. This is best read as digestive-system awareness, not a diagnosis.
This becomes worth discussing if bowel habits change persistently, blood appears in stool, unexplained abdominal pain develops, gallbladder-type pain occurs after meals, or family colorectal history affects screening decisions. Diet quality and fiber consistency are the most practical everyday levers.
What to watch forUse this as digestive-system context, especially if bowel changes, abdominal pain, gallbladder-type symptoms, or family colorectal history becomes relevant.
Show technical evidence
Risk-score evidence
- cholecystitis: risk percentile 94.5%, coverage 88%, PGS000942.
- diverticulosis: risk percentile 83.4%, coverage 100%, PGS001857.
- crohn s disease: risk percentile 83.8%, coverage 83%, PGS001331.
- benign neoplasm of colon: risk percentile 8.6%, coverage 100%, PGS001811.
- cholelithiasis and cholecystitis: risk percentile 19.7%, coverage 100%, PGS001861.
- other chronic nonalcoholic liver disease: risk percentile 10.3%, coverage 100%, PGS001860.
Protein pathway context
- CEACAM21: predicted level percentile 8.5%, R2 0.6663; pathway context only.
- DKKL1: predicted level percentile 3.5%, R2 0.8321; pathway context only.
- LECT2: predicted level percentile 17.6%, R2 0.5765; pathway context only.
Candidate variants
- Variant rs11010067 GG: snpedia_context.
Skin and cancer-background awareness
background
The strongest cancer-background signal is skin-related, with additional lung, glioma, testicular, and general cancer-context evidence plus some protective prostate and benign-colon context.
Full explanation
Several cancer-background signals appear, but they should be treated as awareness rather than prediction. The most actionable theme is skin, because the melanoma signal is high and skin protection is a practical low-regret habit.
Other signals include lung, glioma, testicular, and general cancer-context evidence. Protective prostate and benign-colon evidence adds nuance, so this is not a single global cancer-risk conclusion.
This becomes worth discussing if there are changing moles, persistent unexplained lumps, testicular changes, persistent cough, neurological symptoms, strong family history, or screening decisions that depend on risk context. The day-to-day priority is sun protection and avoiding smoke exposure.
What to watch forPrioritize consistent sun protection and use this as context for family-history or symptom-triggered screening conversations.
Show technical evidence
Risk-score evidence
- skin melanoma: risk percentile 95.7%, coverage 98%, PGS003745.
- lung cancer: risk percentile 94.8%, coverage 87%, PGS001392.
- number of self reported cancers: risk percentile 93.3%, coverage 88%, PGS001005.
- prostate cancer: risk percentile 11.4%, coverage 87%, PGS001292.
- benign neoplasm of colon: risk percentile 8.6%, coverage 100%, PGS001811.
Protein pathway context
- DKKL1: predicted level percentile 3.5%, R2 0.8321; pathway context only.
- CEACAM21: predicted level percentile 8.5%, R2 0.6663; pathway context only.
- PRSS53: predicted level percentile 94.8%, R2 0.5164; pathway context only.
- TNN: predicted level percentile 91.5%, R2 0.5604; pathway context only.
Candidate variants
- Variant rs10484561 TT: snpedia_context.
- Variant rs10505483 CC: snpedia_context.
Sleep, stress-sensitivity, and brain-health background
background
Sleepiness, insomnia, stress-sensitivity, tinnitus, hearing, Alzheimer-related, and alcohol-use signals appear alongside protective depression-related and some brain-imaging context.
Full explanation
The brain and behavior evidence is mixed but coherent. It leans toward higher sensitivity in sleep, stress response, daytime alertness, tinnitus or hearing context, and later-life brain-health background.
This is not a diagnosis of anxiety, insomnia, dementia, or any neurodevelopmental condition. Depression-related evidence is protective, and the brain-imaging rows are research context rather than medical conclusions.
This becomes worth discussing if poor sleep causes daytime impairment, stress symptoms become persistent, hearing or tinnitus changes affect life, alcohol use becomes hard to control, memory concerns appear, or family neurodegenerative history is relevant. Sleep regularity and recovery quality are the most practical levers.
What to watch forTreat sleep quality, stress load, hearing changes, and alcohol-use patterns as practical areas to watch, especially if they start affecting daily function.
Show technical evidence
Risk-score evidence
- neuroticism score: risk percentile 99.6%, coverage 100%, PGS001996.
- daytime dozing sleeping: risk percentile 98.9%, coverage 100%, PGS001995.
- sleeplessness insomnia: risk percentile 94.8%, coverage 100%, PGS001932.
- suffer from nerves: risk percentile 97.3%, coverage 90%, PGS001017.
- alzheimers disease: risk percentile 94.9%, coverage 100%, PGS002035.
- amyloid beta 42: risk percentile 81%, coverage 100%, PGS003762.
Protein pathway context
- MDGA1: predicted level percentile 2.8%, R2 0.7077; pathway context only.
- ADGRB3: predicted level percentile 10.3%, R2 0.597; pathway context only.
- PSPN: predicted level percentile 82%, R2 0.5175; pathway context only.
Candidate variants
- CACNA1C rs1006737 GG: snpedia_context; Post-traumatic stress disorder.
- ANK3 rs10994359 TT: snpedia_context.
Spine, connective tissue, and strength resilience
background
Low grip-strength and lean-mass/body-size signals combine with spine, fascia, hernia, tendon-cyst, and tissue-remodeling evidence.
Full explanation
The training-relevant evidence points toward a body that may benefit from deliberate strength development. Grip strength, lean-mass/body-size, and resting-energy signals lean lower, while spine, fascia, hernia, and tendon-cyst signals lean higher.
That combination does not mean injury is expected. It suggests that progressive loading, careful recovery, and connective-tissue tolerance may matter more than chasing volume or intensity too quickly.
This becomes worth discussing if recurring back pain, hernia symptoms, palm-fascia changes, tendon or joint cysts, repeated strains, or training plateaus appear. If anti-inflammatory pain medicines become frequent, medication-processing evidence is also relevant.
What to watch forUse progressive strength training, grip work, loaded carries, and mobility work; slow down progression if tendon, back, hernia, or fascia symptoms appear.
Show technical evidence
Risk-score evidence
- right hand grip strength: risk percentile 95.1%, coverage 92%, PGS001120.
- other intervertebral disk disorders: risk percentile 90.9%, coverage 88%, PGS000932.
- contracture of palmar fascia dupuytren s disease: risk percentile 90.7%, coverage 100%, PGS001880.
- ganglion and cyst of synovium tendon and bursa: risk percentile 90.6%, coverage 100%, PGS001879.
- inguinal hernia: risk percentile 91.8%, coverage 100%, PGS001854.
- fibroblastic disorders: risk percentile 88.5%, coverage 82%, PGS001031.
Protein pathway context
- MMP3: predicted level percentile 96.2%, R2 0.5052; pathway context only.
- TNN: predicted level percentile 91.5%, R2 0.5604; pathway context only.
- CRTAC1: predicted level percentile 13.4%, R2 0.5057; pathway context only.
- PRSS53: predicted level percentile 94.8%, R2 0.5164; pathway context only.
Candidate variants
- PCSK5 rs11144688 GG: snpedia_context.
- SLCO1C1 rs10770705 CC: snpedia_context.
- SUPT3H rs10948222 TT: snpedia_context.
Medication-response context
- CYP2C9: Intermediate Metabolizer, *1/*3; affected medicines include Warfarin, Phenytoin, Celecoxib, Flurbiprofen, Losartan, Simvastatin.
Kidney, urate, and mineral-handling background
background
Urate, cystatin, phosphate, urine-sodium, albumin, and vitamin-D-related signals are elevated, while microalbumin and hematuria context leans protective.
Full explanation
Kidney and mineral-handling evidence is present but not as strongly convergent as the metabolic or vascular categories. It includes urate, cystatin, phosphate, urine-sodium, albumin, and vitamin-D-related signals.
Protective microalbumin and hematuria context softens the interpretation. This is not evidence of kidney disease or a vitamin problem; it is background for how fluid balance, minerals, and urate may be worth interpreting if real lab data ever appears.
This becomes worth discussing if gout-like flares, kidney-stone history, blood-pressure changes, abnormal kidney labs, urine abnormalities, or major diet changes involving alcohol, dehydration, or very high protein intake become relevant.
What to watch forKeep hydration, alcohol moderation, and balanced protein intake in view; review this theme if gout-like symptoms, stones, blood-pressure changes, or kidney-related labs appear.
Show technical evidence
Risk-score evidence
- serum urate: risk percentile 91.8%, coverage 99%, PGS000126.
- cystatin c mg l: risk percentile 80.2%, coverage 93%, PGS000680.
- phosphate mmol l: risk percentile 92.2%, coverage 92%, PGS000692.
- sodium in urine mmol l: risk percentile 92%, coverage 91%, PGS000695.
- microalbumin in urine: risk percentile 6.8%, coverage 100%, PGS001967.
- hematuria: risk percentile 7.4%, coverage 100%, PGS001863.
Protein pathway context
- KLK1: predicted level percentile 87.1%, R2 0.6165; pathway context only.
- CFHR2: predicted level percentile 8.7%, R2 0.7304; pathway context only.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP2C19
RAPID METABOLIZER
*1/*17
Affected drugs: Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole
CYP2C9
INTERMEDIATE METABOLIZER
*1/*3
Affected drugs: Warfarin, Phenytoin, Celecoxib, Flurbiprofen, Losartan, Simvastatin
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
CYP2B6
POOR METABOLIZER
*9/*9
Affected drugs: Efavirenz, Bupropion, Methadone
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.